Number (%) of patients with adverse events related to study drug (n>1 in any group)
| Cohort A | Cohort B | Cohort C | |||
| Efpeglenatide 6 mg QW | Placebo | Efpeglenatide 16 mg QM | Placebo | Liraglutide | |
| Gastrointestinal disorders, n (%) | |||||
| Diarrhea | 5 (38.5) | 1 (25.0) | 7 (53.8) | – | 2 (15.4) |
| Nausea | 5 (38.5) | – | 8 (61.5) | 1 (25.0) | 4 (30.8) |
| Vomiting | 3 (23.1) | – | 6 (46.2) | – | 2 (15.4) |
| Flatulence | 1 (7.7) | – | 4 (30.8) | – | – |
| Abdominal distension | 1 (7.7) | – | 3 (23.1) | – | 2 (15.4) |
| Abdominal pain | – | – | 2 (15.4) | – | – |
| Eructation | – | – | 1 (7.7) | – | 2 (15.4) |
| General disorders and administration site conditions, n (%) | |||||
| Injection site pain | 2 (15.4) | – | 1 (7.7) | 1 (25.0) | – |
| Early satiety | 1 (7.7) | – | 3 (23.1) | – | – |
| Metabolism and nutrition disorders, n (%) | |||||
| Decreased appetite | 4 (30.8) | – | 4 (30.8) | – | 2 (15.4) |
| Hypoglycemia | 7 (53.8) | – | 5 (38.5) | – | 1 (7.7) |
QM, once monthly; QW, once weekly.